Generex Raising $20.7M Privately For Oral-lyn Insulin Spray Trials

Boggs, Jennifer
April 2008
BioWorld Today;4/3/2008, Vol. 19 Issue 65, p3
This article reports on the money being raised by Generex Biotechnology Corp. to support the late-stage trials of Oral-lyn, an insulin spray product for Type I and Type II diabetes patients. Eight percent of convertible notes and warrants will be issued by Generex Biotechnology to existing institutional investors. Shareholder approval will be sought by Generex Biotechnology during its meeting on May 27, 2008.


Related Articles

  • Financings Roundup.  // BioWorld Today;5/21/2009, Vol. 20 Issue 97, p10 

    The article reports on the consummation by Generex Biotechnology Corp. of a $5 million registered direct offering of the company's common stock to selected accredited investors. The offering of the company's common stock is said to have been at discount, had no warrant coverage and covers about...

  • CLINIC ROUNDUP.  // BioWorld Today;6/6/2008, Vol. 19 Issue 110, p7 

    This section offers news briefs on the biotechnology market. Cytokinetics Inc. has announced data from its Phase I/II trial evaluating its drug candidate SB-743921 in the treatment of patients with Hodgkin or non-Hodgkin lymphoma. Emergent BioSolutions Inc. has started dosing of patients in a...

  • Clinic Roundup.  // BioWorld Today;5/23/2013, Vol. 24 Issue 99, p8 

    This section offers updates on biotechnology sector clinical progress as of May 23, 2013. Acelrx Pharmaceuticals Inc. reported on the results of a Phase III study with its Sufentanil NanoTab patient-controlled analgesia (PCA) system. Agenus Inc. announced the start of a Phase II study with a...

  • CLINIC ROUNDUP.  // BioWorld Today;11/6/2007, Vol. 18 Issue 216, p8 

    This section presents news briefs on the biotechnology industry. Emergent BioSolutions Inc. has completed a human study to support the expansion of BioThrax, anthrax vaccine absorbed, in post-exposure prophylaxis in people exposed to anthrax. Epeius Biotechnologies Corp. has opened a Phase II...

  • GENEREX GETS APPROVAL FOR ORAL-LYN PHASE III TRIAL.  // Worldwide Biotech;Mar2008, Vol. 20 Issue 3, p4 

    The article reports on the approval given by Ukraine's Ministry of Health to Generex Biotechnology Corporation for the conduct of a Phase III clinical trial for Generex Oral-lynâ„¢ at several clinical sites in the country. Generex has plans to conduct trials in seven countries. Type-1...

  • life sciences In Brief.  // Chemical Market Reporter;3/21/2005, Vol. 267 Issue 12, p8 

    The article presents information on recent developments related to life sciences. Astralis Ltd. says that preliminary results from a Phase II study of its product candidate, a novel immuno-stimulatory product for psoriasis, did not meet its primary endpoint. Generex Biotechnology Corp. reports...

  • CLINIC ROUNDUP.  // BioWorld Today;5/11/2010, Vol. 21 Issue 90, p2 

    This section offers news briefs on clinical trials including the completion by Generex Biotechnology Corp. of enrollment of patients in its Phase III trial of Generex Oral-lyn and the encouraging pharmacokinetic results obtained by QRxPharma Inc. from its trial of a controlled-release dual-opioid.

  • Clinic Roundup.  // BioWorld Today;9/19/2011, Vol. 22 Issue 181, p3 

    This section offers news briefs on the biotechnology industry as of September 19, 2011, including a trial of Generex Oral-lyn, a buccal spray insulin, by Generex Biotechnology Corp. and a Phase II/III trial of a vaccine for Japanese encephalitis completed by Intercell AG and Biological E. Ltd.

  • Financings Roundup.  // BioWorld Today;8/10/2012, Vol. 23 Issue 155, p6 

    This article reports on a securities purchase agreement made by Generex Biotechnology Corp. with some institutional investors in August 2012.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics